RSM conducted financial due diligence for ProductLife Group during the acquisition of Nextep

RSM, , the 6th largest global network in advisory and audit, performed buy-side financial due diligence for ProductLife Group, a global provider of regulatory, scientific, compliance, and digital transformation consulting services for the life sciences industry, during the acquisition of Nextep, a French consulting firm specialized in market access and public affairs.

ProductLife Group was supported by an RSM team under the supervision of Eric Fougedoire, RSM partner.

The acquisition of Nextep marks the seventh external growth transaction entrusted to RSM's Corporate Finance division.

Through this new operation, RSM strengthens its advisory role with regulatory consulting players in the life sciences sector during their strategic acquisitions.

ProductLife Group (PLG), a global leader in digital transformation, regulatory, scientific, and compliance consulting for the life sciences industry, is pleased to announce the acquisition of Nextep, a renowned French consulting firm specializing in market access and public affairs.

Founded in 1999 by Guillaume Bouchara, Nextep is recognized for helping its clients tackle complex challenges related to patient access and public policy in the pharmaceutical, biotechnology, and medical device industries. With a team of 45 professionals and more than 100 clients, Nextep has established a strong presence in France, making this acquisition a strategic strengthening of PLG’s global market access capabilities.

This acquisition continues the company’s growth in key global markets, following recent acquisitions of Intexo in Italy, Outcomes10 in Spain, and Commercial Eyes in Australia. PLG is now one of Europe’s largest providers of global value strategy and market access consulting.

Obtaining favorable market access is critical in today’s highly competitive clinical development environment. However, it is also a challenge and requires in-depth regional expertise. The acquisition of Nextep fits into this approach, increasing and expanding the localized support for market access, product launch, and regulatory services that PLG can offer on a global scale.

Guillaume Bouchara, founder and president of Nextep, commented: “This growth project aligns perfectly with our commitment to continuously improving the services we offer our clients, with the goal of facilitating patient access to innovations and the best possible care in France, Europe, and beyond.”

Xavier Duburcq, CEO of PLG, stated: “Both companies share a long reputation for scientific rigor and customer service. We are proud to play a key role in enhancing how sponsors access markets and transform the lives of patients. Together, we will continue to generate a positive impact and expand access to therapeutic solutions by collaborating with physicians, research institutes, companies, health authorities, and patients.”

Mariangela Prada, Head of Market Access at PLG, added : “We are excited to welcome the Nextep teams into PLG, as together we can now offer exceptional local service while meeting our clients’ global needs. For sponsors, this means a broader strategic offering, deeper connectivity with world-class expertise, and better product launch success. With upcoming changes to EU health technology assessments, this acquisition is an important step in strengthening our pan-European platform and supporting our clients in this evolving environment.